Mind Medicine (MindMed), Inc. MNMD 深 沪
等待开盘 04-01 09:30:00 美东时间
15.02
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 15.02
- 总市值 11.43亿
- 52周最高 15.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.70
- 委 比 0.00%
- 总股本 7608.79万
- 历史最高 86.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.20
- 每 手 1
- 风险率 2.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
03-28 01:28
LSD therapy biotech Definium sued for alleged trade secret theft
LSD therapy biotech Definium sued for alleged trade secret theft By Blake Brittain Feb 2 (Reuters) - A clinical-trial provider sued psychedelic therapy developer Definium Therapeutics DFTX.O on Monday in Delaware federal court, claiming it stole trade secrets related to LSD trials to share with a up
02-03 06:05
Definium Therapeutics (Formerly Mind Medicine) Updates Nasdaq Listing Timeline; Common Shares To Begin Trading Under Ticker DFTX On January 15
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or "Definium") is updating its previous announcement that the Company's Common Shares would begin trading on Nasdaq under the ticker
01-13 20:20
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
Mind Medicine ( ($MNMD) ) just unveiled an announcement. On January 9, 2026, th...
01-12 21:56
Ametek, MindMed, Atai, Prime and KB Home Trending
Analysts are intrested in these 5 stocks: ( ($AME) ), ( ($MNMD) ), ( ($ATAI) ),...
2025-12-27 17:02
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Psyence Biomedical Ltd., a biopharmaceutical company, announced that its nature-derived psilocybin product has been approved for use in its Phase IIb clinical trial for treating Adjustment Disorder in cancer patients. With $9.5 million in cash reserves and no debt, the company is vertically integrated, positioning it as a leader in the psychedelics sector. The trial, conducted at multiple sites, aims to evaluate psilocybin-assisted psychotherapy ...
2025-12-19 12:00
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
2025-12-18 01:42
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
